Comment
doi: 10.1056/NEJMc1503223.
Factor XI antisense oligonucleotide for venous thrombosis
- PMID: 25901434
- DOI: 10.1056/NEJMc1503223
Item in Clipboard
Comment
Factor XI antisense oligonucleotide for venous thrombosis
N Engl J Med.
.
No abstract available
Comment on
-
Factor XI antisense oligonucleotide for prevention of venous thrombosis.N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7. N Engl J Med. 2015. PMID: 25482425 Free PMC article. Clinical Trial.
-
Factor XI antisense oligonucleotide for venous thrombosis.N Engl J Med. 2015 Apr 23;372(17):1671. doi: 10.1056/NEJMc1503223. N Engl J Med. 2015. PMID: 25901435 No abstract available.
-
Factor XI antisense oligonucleotide for venous thrombosis.N Engl J Med. 2015 Apr 23;372(17):1671-2. doi: 10.1056/NEJMc1503223. N Engl J Med. 2015. PMID: 25901436 No abstract available.
Similar articles
-
Factor XI antisense oligonucleotide for venous thrombosis.N Engl J Med. 2015 Apr 23;372(17):1671-2. doi: 10.1056/NEJMc1503223. N Engl J Med. 2015. PMID: 25901436 No abstract available.
-
Factor XI antisense oligonucleotide for venous thrombosis.N Engl J Med. 2015 Apr 23;372(17):1671. doi: 10.1056/NEJMc1503223. N Engl J Med. 2015. PMID: 25901435 No abstract available.
-
Anticoagulation therapy: Reducing factor XI with antisense oligonucleotides superior to endoxaparin for postoperative venous thromboembolism.Nat Rev Cardiol. 2015 Feb;12(2):66. doi: 10.1038/nrcardio.2014.214. Epub 2014 Dec 23. Nat Rev Cardiol. 2015. PMID: 25533800 No abstract available.
-
Factor XI and factor XII as targets for new anticoagulants.Thromb Res. 2016 May;141 Suppl 2:S40-5. doi: 10.1016/S0049-3848(16)30363-2. Thromb Res. 2016. PMID: 27207423 Review.
-
[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].Ugeskr Laeger. 2005 May 23;167(21):2261-5. Ugeskr Laeger. 2005. PMID: 15962850 Review. Danish. No abstract available.
Cited by
-
Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability.Blood. 2019 Jan 31;133(5):481-493. doi: 10.1182/blood-2018-07-861237. Epub 2018 Nov 15. Blood. 2019. PMID: 30442678 Free PMC article.
-
Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.J Thromb Haemost. 2021 Apr;19(4):1001-1017. doi: 10.1111/jth.15236. Epub 2021 Feb 10. J Thromb Haemost. 2021. PMID: 33421301 Free PMC article.
-
Factor XI: structure, function and therapeutic inhibition.J Thromb Thrombolysis. 2024 Dec;57(8):1315-1328. doi: 10.1007/s11239-024-02972-5. Epub 2024 Apr 16. J Thromb Thrombolysis. 2024. PMID: 38622277 Free PMC article. Review.
-
Antisense technology: A review.J Biol Chem. 2021 Jan-Jun;296:100416. doi: 10.1016/j.jbc.2021.100416. Epub 2021 Feb 16. J Biol Chem. 2021. PMID: 33600796 Free PMC article. Review.
-
Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.Intractable Rare Dis Res. 2016 Aug;5(3):168-76. doi: 10.5582/irdr.2016.01056. Intractable Rare Dis Res. 2016. PMID: 27672539 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
